| Literature DB >> 31218672 |
Joanna Bem1, Nikola Brożko1, Chaitali Chakraborty1, Marcin A Lipiec1, Kamil Koziński1, Andrzej Nagalski1, Łukasz M Szewczyk1, Marta B Wiśniewska1.
Abstract
Canonical Wnt signaling, which is transduced by β-catenin and lymphoid enhancer factor 1/T cell-specific transcription factors (LEF1/TCFs), regulates many aspects of metazoan development and tissue renewal. Although much evidence has associated canonical Wnt/β-catenin signaling with mood disorders, the mechanistic links are still unknown. Many components of the canonical Wnt pathway are involved in cellular processes that are unrelated to classical canonical Wnt signaling, thus further blurring the picture. The present review critically evaluates the involvement of classical Wnt/β-catenin signaling in developmental processes that putatively underlie the pathology of mental illnesses. Particular attention is given to the roles of LEF1/TCFs, which have been discussed surprisingly rarely in this context. Highlighting recent discoveries, we propose that alterations in the activity of LEF1/TCFs, and particularly of transcription factor 7-like 2 (TCF7L2), result in defects previously associated with neuropsychiatric disorders, including imbalances in neurogenesis and oligodendrogenesis, the functional disruption of thalamocortical circuitry and dysfunction of the habenula.Entities:
Keywords: TCF7L2; Wnt pathway; beta-catenin; brain development; habenula; mental disorders; neurogenesis; oligodendrogenesis; postmitotic differentiation; thalamus
Mesh:
Substances:
Year: 2019 PMID: 31218672 PMCID: PMC6772062 DOI: 10.1002/1873-3468.13502
Source DB: PubMed Journal: FEBS Lett ISSN: 0014-5793 Impact factor: 4.124
Figure 1Canonical Wnt/β‐catenin and divergent signaling pathways. The binding of a Wnt ligand to a Frizzled receptor and LRP5/6 co‐receptor, followed by the recruitment of DVL to the receptor complex, leads to translocation and inhibition of the destruction complex, which consists of the kinase GSK3α/β, Adenomatous Polyposis Coli (APC) and Axin. The phosphorylation of β‐catenin by GSK3α/β in the active destruction complex primes this protein for proteasomal degradation (not shown). Upon inhibition of the complex, β‐catenin accumulates in the cytoplasm and translocates into the nucleus where it activates gene transcription as a co‐activator of LEF1/TCFs. This canonical pathway can branch downstream (a) GSK3α/β inhibition (e.g., to slow protein degradation during mitosis, activate the mTOR pathway, or stabilize the cytoskeleton), (b) β‐catenin stabilization (e.g., to stabilize cell adhesion with cadherins or facilitate the assembly of PDZ domain‐containing proteins), and (c) β‐catenin nuclear translocation (to activate gene transcription by interacting with nuclear receptors, FOXO and other transcription factors).
Figure 2Location of single nucleotide polymorphisms (SNPs) in the human TCF7L2 gene. Representative intron–exon structure of the TCF7L2 gene. Long introns are represented by a double slash. Blue boxes indicate the alternatively spliced exons, blue arrows represent alternative transcription start sites. Important protein domains are marked by red boxes: β‐catenin binding domain, and DNA binding domain ‐ HMG‐box. Black arrows indicate the location of SNPs or mutations.
Wnt pathway genes and genetic modifications mentioned in this review. LOF, loss‐of‐function mutation; GOF, gain‐of‐function mutation.
| Mutation | Explanation | Targeted Wnt pathways | Expected effect on the canonical Wnt/β‐catenin pathway |
|---|---|---|---|
| Upstream components of the canonical Wnt pathway | |||
|
| GOF | Canonical and divergent canonical | Upregulation |
|
| GOF | Canonical and divergent canonical | Upregulation |
|
| LOF | Canonical and divergent canonical | Downregulation |
|
| LOF | Canonical and divergent canonical | Downregulation |
|
| GOF; | Canonical and divergent canonical | Downregulation |
| GSK3α/β, a component of β‐catenin destruction complex | |||
|
| LOF | Canonical and divergent canonical | Upregulation |
| GSK3β K85A/K86A | LOF, dominan negative mutant; lysine‐to‐alanine mutations to produce catalytically inactive GSK3β | Canonical and divergent canonical | Upregulation |
|
| GOF | Canonical and divergent canonical | Downregulation |
| GSK3α S21A and GSK3/β S9A | GOF; serine‐to‐alanine mutations to block inhibitory serine phosphorylation of GSK3α and β | Canonical and divergent canonical | Downregulation |
|
| GOF; serine‐to‐alanine mutation to block inhibitory serine phosphorylation of GSK3β | Canonical and divergent canonical | Downregulation |
| Dishevelled (DVL), an inhibitor of β‐catenin destruction complex | |||
|
| LOF | Canonical and divergent canonical | Downregulation |
| β‐catenin ( | |||
|
| LOF | Canonical Wnt/β‐catenin, divergent Wnt/β‐catenin, Wnt‐independent | Downregulation |
|
| LOF, transcriptionally nonfunctional β‐catenin with intact adhesive function; deletions of N‐terminal and C‐terminal transactivation domains | Canonical Wnt/β‐catenin | Downregulation |
|
| GOF, a stabilized form of β‐catenin; deletion of exon3 that encodes the GSK3α/β phosphorylation sites | Canonical Wnt/β‐catenin and divergent Wnt/β‐catenin | Upregulation |
|
| GOF, a stabilized form of β‐catenin; deletion of N‐terminal fragment that contains GSK3α/β phosphorylation sites | Canonical Wnt/β‐catenin and divergent Wnt/β‐catenin | Upregulation |
|
| GOF, a stabilized form of β‐catenin with; deletion of 29–48 aminoacid residues that contain GSK3α/β phosphorylation sites | Canonical Wnt/β‐catenin and divergent Wnt/β‐catenin | Upregulation |
|
| GOF, a stabilized form of β‐catenin; serine‐to‐phenylalanine or serine‐to‐tyrosine mutation in GSK3α/β phosphorylation sites | Canonical Wnt/β‐catenin and divergent Wnt/β‐catenin | Upregulation |
|
| GOF; β‐catenin activation domain coupled with LEF1 | Canonical Wnt/β‐catenin | Upregulation |
| LEF/TCF transcription factors | |||
|
| LOF | Canonical Wnt/β‐catenin and Wnt‐independent | Downregulation |
|
| LOF | Canonical Wnt/β‐catenin and Wnt‐independent | Downregulation |
|
| LOF | Canonical Wnt/β‐catenin and Wnt‐independent | Upregulation |
| dnLEF1 | LOF, a dominant negative form of LEF1; LEF1 with a truncated β‐catenin‐binding domain | Canonical Wnt/β‐catenin | Downregulation |
| dnTCF7L2 | LOF, a dominant negative form of TCF7L2; TCF7L2 with a truncated β‐catenin‐binding domain | Canonical Wnt/β‐catenin | Downregulation |
| TCF7L2ΔHMG | LOF; TCF7L2 without the DNA binding domain (HMG), likely act as a dominant negative mutant | Canonical Wnt/β‐catenin and Wnt‐independent | Downregulation |
| LEF1ΔHMG | LOF; LEF1 without the DNA binding domain (HMG), likely act as a dominant negative mutant | Canonical Wnt/β‐catenin and Wnt‐independent | Downregulation |
|
| GOF; LEF1 fused to the herpes simplex virus VP16 transactivation domain | Canonical Wnt/β‐catenin and Wnt‐independent | Upregulation |
Figure 3Role of Wnt/β‐catenin signaling and TCF7L2 in neurogenesis and gliogenesis in the neocortex. The process of developmental neurogenesis and gliogenesis in the neocortex is opposite to the temporal gradient of Wnt signaling (shown in yellow). Genetic manipulation to downregulate Wnt/β‐catenin signaling causes premature neurogenic divisions of uncommitted progenitors (RG) and a shorter time of neurogenesis as a consequence of precocious astrogenesis. Wnt/β‐catenin signaling inhibits oligodendrocyte precursor cell (OPC) differentiation. This is antagonized by interactions between TCF7L2 and the Kaiso co‐repressor. TCF7L2 interacts with the SOX10 to promote the further differentiation of iOL into mOL in a β‐catenin‐independent manner. Steps in this process that were shown to be activated or inhibited by Wnt/β‐catenin signaling or TCF7L2 are indicated in green with arrows and red bar‐headed lines, respectively. GP, glial progenitor
Figure 4Role of TCF7L2 in the developing thalamus and habenula. Early knockout of Tcf7l2 impairs segregation of cells in the thalamo‐habenular primordium (upper and middle panel), and disrupts axon growth and regional cell identities (middle panel). Conditional postnatal knockout of Tcf7l2 impairs intrinsic excitability of thalamo‐cortical relay neurons (bottom panel).